Stanford blocks 15-PGDH to regenerate hyaline cartilage in aged mice and human explants

{"The team administered a small-molecule 15-PGDH inhibitor to 18-month-old mice with spontaneous cartilage loss and to younger mice after ACL-like injury. Treated animals showed increased chondrocyte proliferation, elevated collagen-II and aggrecan expression, and near-complete restoration of joint surface integrity measured by histology and micro-CT. Human osteoarthritic cartilage explants cultured with the inhibitor likewise upregulated matrix genes and deposited new glycosaminoglycans within two weeks.","Unlike prior stem-cell or growth-factor approaches that failed to produce stable hyaline matrix, 15-PGDH blockade acted directly on resident chondrocytes, shifting their transcriptome toward a younger state without detectable stem-cell recruitment. This mechanism explains the durable repair observed and differentiates the strategy from symptom-modifying drugs now in trials. Economic modeling suggests an effective injectable could avert 30-40% of the 800,000 annual U.S. knee replacements if durable benefit is confirmed.","The principal limitation is the absence of large-animal pharmacokinetic and toxicity data; mouse joints heal more readily than human ones. A phase-1 safety study in patients scheduled for total knee arthroplasty, using serial MRI and biopsy endpoints, is required before any claim of disease modification can be advanced.","Next steps include GMP synthesis of the lead compound and IND-enabling studies already underway at the Baxter Laboratory."}